ID   OPRM_RAT                Reviewed;         398 AA.
AC   P33535; Q2TV20; Q2TV21; Q4VWM5; Q4VWM7; Q4VWX7; Q4VWX8; Q62846; Q64064;
AC   Q64120;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   02-OCT-2024, entry version 188.
DE   RecName: Full=Mu-type opioid receptor;
DE            Short=M-OR-1;
DE            Short=MOR-1;
DE   AltName: Full=Opioid receptor B;
GN   Name=Oprm1; Synonyms=Ror-b;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8394245; DOI=10.1016/0014-5793(93)81011-n;
RA   Fukuda K., Kato S., Mori K., Nishi M., Takeshima H.;
RT   "Primary structures and expression from cDNAs of rat opioid receptor
RT   delta- and mu-subtypes.";
RL   FEBS Lett. 327:311-314(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8234282; DOI=10.1073/pnas.90.21.10230;
RA   Wang J.-B., Imai Y., Epler M.C., Gregor P., Spivak C., Uhl G.R.;
RT   "Mu opiate receptor: cDNA cloning and expression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10230-10234(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Brain;
RX   PubMed=8393525;
RA   Chen Y., Mestek A., Liu J., Hurley J.A., Yu L.;
RT   "Molecular cloning and functional expression of a mu-opioid receptor from
RT   rat brain.";
RL   Mol. Pharmacol. 44:8-12(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Bunzow J.R., Grandy D.K., Kelly M.;
RL   Submitted (SEP-1993) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION.
RC   STRAIN=Sprague-Dawley; TISSUE=Olfactory bulb;
RX   PubMed=8240812; DOI=10.1016/0896-6273(93)90120-g;
RA   Thompson R.C., Mansour A., Akil H., Watson S.J.;
RT   "Cloning and pharmacological characterization of a rat mu opioid
RT   receptor.";
RL   Neuron 11:903-913(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8189219; DOI=10.1046/j.1471-4159.1994.62062099.x;
RA   Zastawny R.L., George S.R., Nguyen T., Cheng R., Tsatsos J.,
RA   Briones-Urbina R., O'Dowd B.F.;
RT   "Cloning, characterization, and distribution of a mu-opioid receptor in rat
RT   brain.";
RL   J. Neurochem. 62:2099-2105(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 5).
RC   STRAIN=Sprague-Dawley;
RA   Pan Y.-X., Xu J., Pasternak G.W.;
RT   "Identification and characterization of two new alternatively spliced
RT   variants from the rat mu opioid receptor gene, Oprm.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 6; 7 AND 8).
RC   STRAIN=Sprague-Dawley;
RX   PubMed=15525342; DOI=10.1111/j.1471-4159.2004.02767.x;
RA   Pasternak D.A., Pan L., Xu J., Yu R., Xu M.M., Pasternak G.W., Pan Y.X.;
RT   "Identification of three new alternatively spliced variants of the rat mu
RT   opioid receptor gene: dissociation of affinity and efficacy.";
RL   J. Neurochem. 91:881-890(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 101-340.
RC   TISSUE=Macrophage;
RX   PubMed=7733926; DOI=10.1006/bbrc.1995.1538;
RA   Sedqi M., Roy S., Ramakrishnan S., Elde R., Loh H.H.;
RT   "Complementary DNA cloning of a mu-opioid receptor from rat peritoneal
RT   macrophages.";
RL   Biochem. Biophys. Res. Commun. 209:563-574(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 356-398 (ISOFORM 4).
RX   PubMed=7532594; DOI=10.1016/0014-5793(95)00028-8;
RA   Zimprich A., Simon T., Hoellt V.;
RT   "Cloning and expression of an isoform of the rat mu opioid receptor
RT   (rMOR1B) which differs in agonist induced desensitization from rMOR1.";
RL   FEBS Lett. 359:142-146(1995).
RN   [12]
RP   FUNCTION.
RX   PubMed=1846076; DOI=10.1016/0896-6273(91)90117-i;
RA   Schroeder J.E., Fischbach P.S., Zheng D., McCleskey E.W.;
RT   "Activation of mu opioid receptors inhibits transient high- and low-
RT   threshold Ca2+ currents, but spares a sustained current.";
RL   Neuron 6:13-20(1991).
RN   [13]
RP   FUNCTION.
RX   PubMed=7678862; DOI=10.1523/jneurosci.13-02-00867.1993;
RA   Schroeder J.E., McCleskey E.W.;
RT   "Inhibition of Ca2+ currents by a mu-opioid in a defined subset of rat
RT   sensory neurons.";
RL   J. Neurosci. 13:867-873(1993).
RN   [14]
RP   FUNCTION, AND MUTAGENESIS OF ASP-114; ASP-147 AND HIS-297.
RX   PubMed=8051154; DOI=10.1016/s0021-9258(17)32028-8;
RA   Surratt C.K., Johnson P.S., Moriwaki A., Seidleck B.K., Blaschak C.J.,
RA   Wang J.B., Uhl G.R.;
RT   "-mu opiate receptor. Charged transmembrane domain amino acids are critical
RT   for agonist recognition and intrinsic activity.";
RL   J. Biol. Chem. 269:20548-20553(1994).
RN   [15]
RP   FUNCTION.
RX   PubMed=8624732; DOI=10.1016/0006-8993(95)00928-j;
RA   Mansour A., Hoversten M.T., Taylor L.P., Watson S.J., Akil H.;
RT   "The cloned mu, delta and kappa receptors and their endogenous ligands:
RT   evidence for two opioid peptide recognition cores.";
RL   Brain Res. 700:89-98(1995).
RN   [16]
RP   FUNCTION, AND COUPLING TO G-PROTEINS.
RX   PubMed=7595566; DOI=10.1046/j.1471-4159.1995.65062682.x;
RA   Chan J.S., Chiu T.T., Wong Y.H.;
RT   "Activation of type II adenylyl cyclase by the cloned mu-opioid receptor:
RT   coupling to multiple G proteins.";
RL   J. Neurochem. 65:2682-2689(1995).
RN   [17]
RP   FUNCTION, AND MUTAGENESIS OF ASP-114.
RX   PubMed=9224819; DOI=10.1124/mol.52.1.105;
RA   Chakrabarti S., Yang W., Law P.Y., Loh H.H.;
RT   "The mu-opioid receptor down-regulates differently from the delta-opioid
RT   receptor: requirement of a high affinity receptor/G protein complex
RT   formation.";
RL   Mol. Pharmacol. 52:105-113(1997).
RN   [18]
RP   PALMITOYLATION, AND MUTAGENESIS OF CYS-346 AND CYS-351.
RX   PubMed=9877183; DOI=10.1016/s0014-5793(98)01547-6;
RA   Chen C., Shahabi V., Xu W., Liu-Chen L.Y.;
RT   "Palmitoylation of the rat mu opioid receptor.";
RL   FEBS Lett. 441:148-152(1998).
RN   [19]
RP   COUPLING TO GNA15, AND FUNCTION.
RX   PubMed=9572309;
RA   Lee J.W., Joshi S., Chan J.S., Wong Y.H.;
RT   "Differential coupling of mu-, delta-, and kappa-opioid receptors to G
RT   alpha16-mediated stimulation of phospholipase C.";
RL   J. Neurochem. 70:2203-2211(1998).
RN   [20]
RP   PHOSPHORYLATION, AND MUTAGENESIS OF TYR-91; TYR-96; TYR-166; TYR-336 AND
RP   THR-394.
RX   PubMed=10488100; DOI=10.1074/jbc.274.39.27610;
RA   Pak Y., O'Dowd B.F., Wang J.B., George S.R.;
RT   "Agonist-induced, G protein-dependent and -independent down-regulation of
RT   the mu opioid receptor. The receptor is a direct substrate for protein-
RT   tyrosine kinase.";
RL   J. Biol. Chem. 274:27610-27616(1999).
RN   [21]
RP   PHOSPHORYLATION AT THR-394, AND MUTAGENESIS OF THR-394.
RX   PubMed=10820022; DOI=10.1021/bi991938b;
RA   Deng H.B., Yu Y., Pak Y., O'Dowd B.F., George S.R., Surratt C.K., Uhl G.R.,
RA   Wang J.B.;
RT   "Role for the C-terminus in agonist-induced mu opioid receptor
RT   phosphorylation and desensitization.";
RL   Biochemistry 39:5492-5499(2000).
RN   [22]
RP   RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION WITH OPRD1.
RX   PubMed=10842167; DOI=10.1074/jbc.m000345200;
RA   George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., O'Dowd B.F.;
RT   "Oligomerization of mu- and delta-opioid receptors. Generation of novel
RT   functional properties.";
RL   J. Biol. Chem. 275:26128-26135(2000).
RN   [23]
RP   PHOSPHORYLATION BY GRK2.
RX   PubMed=10744734; DOI=10.1074/jbc.275.14.10443;
RA   Carman C.V., Barak L.S., Chen C., Liu-Chen L.Y., Onorato J.J.,
RA   Kennedy S.P., Caron M.G., Benovic J.L.;
RT   "Mutational analysis of Gbetagamma and phospholipid interaction with G
RT   protein-coupled receptor kinase 2.";
RL   J. Biol. Chem. 275:10443-10452(2000).
RN   [24]
RP   MUTAGENESIS OF ASP-147 AND ASP-164.
RX   PubMed=11580279; DOI=10.1021/bi0100945;
RA   Li J., Huang P., Chen C., de Riel J.K., Weinstein H., Liu-Chen L.Y.;
RT   "Constitutive activation of the mu opioid receptor by mutation of
RT   D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of
RT   the inactive form of the receptor and for its expression.";
RL   Biochemistry 40:12039-12050(2001).
RN   [25]
RP   MUTAGENESIS OF THR-279.
RX   PubMed=11695897; DOI=10.1021/bi010917q;
RA   Huang P., Li J., Chen C., Visiers I., Weinstein H., Liu-Chen L.Y.;
RT   "Functional role of a conserved motif in TM6 of the rat mu opioid receptor:
RT   constitutively active and inactive receptors result from substitutions of
RT   Thr6.34(279) with Lys and Asp.";
RL   Biochemistry 40:13501-13509(2001).
RN   [26]
RP   FUNCTION, AND MUTAGENESIS OF THR-180.
RX   PubMed=11060299; DOI=10.1074/jbc.m007437200;
RA   Celver J.P., Lowe J., Kovoor A., Gurevich V.V., Chavkin C.;
RT   "Threonine 180 is required for G-protein-coupled receptor kinase 3- and
RT   beta-arrestin 2-mediated desensitization of the mu-opioid receptor in
RT   Xenopus oocytes.";
RL   J. Biol. Chem. 276:4894-4900(2001).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION AT SER-363; THR-370 AND SER-375, AND MUTAGENESIS
RP   OF SER-363; THR-370 AND SER-375.
RX   PubMed=11278523; DOI=10.1074/jbc.m009571200;
RA   El Kouhen R., Burd A.L., Erickson-Herbrandson L.J., Chang C.Y., Law P.Y.,
RA   Loh H.H.;
RT   "Phosphorylation of Ser363, Thr370, and Ser375 residues within the carboxyl
RT   tail differentially regulates mu-opioid receptor internalization.";
RL   J. Biol. Chem. 276:12774-12780(2001).
RN   [28]
RP   MUTAGENESIS OF LEU-275 AND THR-279.
RX   PubMed=12356297; DOI=10.1021/bi026067b;
RA   Huang P., Visiers I., Weinstein H., Liu-Chen L.Y.;
RT   "The local environment at the cytoplasmic end of TM6 of the mu opioid
RT   receptor differs from those of rhodopsin and monoamine receptors:
RT   introduction of an ionic lock between the cytoplasmic ends of helices 3 and
RT   6 by a L6.30(275)E mutation inactivates the mu opioid receptor and reduces
RT   the constitutive activity of its T6.34(279)K mutant.";
RL   Biochemistry 41:11972-11980(2002).
RN   [29]
RP   FUNCTION, RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION WITH SSTR2.
RX   PubMed=11896051; DOI=10.1074/jbc.m110373200;
RA   Pfeiffer M., Koch T., Schroder H., Laugsch M., Hollt V., Schulz S.;
RT   "Heterodimerization of somatostatin and opioid receptors cross-modulates
RT   phosphorylation, internalization, and desensitization.";
RL   J. Biol. Chem. 277:19762-19772(2002).
RN   [30]
RP   INTERACTION WITH PLD2.
RX   PubMed=12519790; DOI=10.1074/jbc.m206709200;
RA   Koch T., Brandenburg L.O., Schulz S., Liang Y., Klein J., Hollt V.;
RT   "ADP-ribosylation factor-dependent phospholipase D2 activation is required
RT   for agonist-induced mu-opioid receptor endocytosis.";
RL   J. Biol. Chem. 278:9979-9985(2003).
RN   [31]
RP   RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION WITH ADRA2A.
RX   PubMed=14645661; DOI=10.1124/mol.64.6.1317;
RA   Jordan B.A., Gomes I., Rios C., Filipovska J., Devi L.A.;
RT   "Functional interactions between mu opioid and alpha 2A-adrenergic
RT   receptors.";
RL   Mol. Pharmacol. 64:1317-1324(2003).
RN   [32]
RP   RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION WITH CCR5.
RX   PubMed=14729105; DOI=10.1016/j.ejphar.2003.10.033;
RA   Chen C., Li J., Bot G., Szabo I., Rogers T.J., Liu-Chen L.Y.;
RT   "Heterodimerization and cross-desensitization between the mu-opioid
RT   receptor and the chemokine CCR5 receptor.";
RL   Eur. J. Pharmacol. 483:175-186(2004).
RN   [33]
RP   INTERACTION WITH GNAS.
RX   PubMed=15857684; DOI=10.1016/j.molbrainres.2004.12.016;
RA   Chakrabarti S., Regec A., Gintzler A.R.;
RT   "Biochemical demonstration of mu-opioid receptor association with Gsalpha:
RT   enhancement following morphine exposure.";
RL   Brain Res. Mol. Brain Res. 135:217-224(2005).
RN   [34]
RP   FUNCTION.
RX   PubMed=15944153; DOI=10.1074/jbc.m502593200;
RA   Belcheva M.M., Clark A.L., Haas P.D., Serna J.S., Hahn J.W., Kiss A.,
RA   Coscia C.J.;
RT   "Mu and kappa opioid receptors activate ERK/MAPK via different protein
RT   kinase C isoforms and secondary messengers in astrocytes.";
RL   J. Biol. Chem. 280:27662-27669(2005).
RN   [35]
RP   FUNCTION, RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION WITH OPRD1.
RX   PubMed=17384143; DOI=10.1096/fj.06-7793com;
RA   Rozenfeld R., Devi L.A.;
RT   "Receptor heterodimerization leads to a switch in signaling: beta-
RT   arrestin2-mediated ERK activation by mu-delta opioid receptor
RT   heterodimers.";
RL   FASEB J. 21:2455-2465(2007).
RN   [36]
RP   INTERACTION WITH GPM6A.
RX   PubMed=17548356; DOI=10.1074/jbc.m700941200;
RA   Wu D.F., Koch T., Liang Y.J., Stumm R., Schulz S., Schroder H., Hollt V.;
RT   "Membrane glycoprotein M6a interacts with the micro-opioid receptor and
RT   facilitates receptor endocytosis and recycling.";
RL   J. Biol. Chem. 282:22239-22247(2007).
RN   [37]
RP   INTERACTION WITH SYP.
RX   PubMed=17005904; DOI=10.1124/mol.106.026062;
RA   Liang Y.J., Wu D.F., Yang L.Q., Hollt V., Koch T.;
RT   "Interaction of the mu-opioid receptor with synaptophysin influences
RT   receptor trafficking and signaling.";
RL   Mol. Pharmacol. 71:123-131(2007).
RN   [38]
RP   FUNCTION, RECEPTOR HETEROOLIGOMERIZATION, AND INTERACTION WITH CNR1.
RX   PubMed=16682964; DOI=10.1038/sj.bjp.0706757;
RA   Rios C., Gomes I., Devi L.A.;
RT   "mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition
RT   of receptor signaling and neuritogenesis.";
RL   Br. J. Pharmacol. 148:387-395(2006).
RN   [39]
RP   FUNCTION, AND MUTAGENESIS OF SER-363; THR-370 AND SER-375.
RX   PubMed=18558479; DOI=10.1016/j.cellsig.2008.05.004;
RA   Chu J., Zheng H., Loh H.H., Law P.Y.;
RT   "Morphine-induced mu-opioid receptor rapid desensitization is independent
RT   of receptor phosphorylation and beta-arrestins.";
RL   Cell. Signal. 20:1616-1624(2008).
RN   [40]
RP   FUNCTION.
RX   PubMed=17947509; DOI=10.1124/mol.107.039842;
RA   Zheng H., Loh H.H., Law P.Y.;
RT   "Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-
RT   regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-
RT   dependent ERK activation.";
RL   Mol. Pharmacol. 73:178-190(2008).
RN   [41]
RP   INTERACTION WITH RGS4.
RX   PubMed=19324084; DOI=10.1016/j.cellsig.2009.03.013;
RA   Leontiadis L.J., Papakonstantinou M.P., Georgoussi Z.;
RT   "Regulator of G protein signaling 4 confers selectivity to specific G
RT   proteins to modulate mu- and delta-opioid receptor signaling.";
RL   Cell. Signal. 21:1218-1228(2009).
RN   [42]
RP   PHOSPHORYLATION AT TYR-166, AND MUTAGENESIS OF TYR-166.
RX   PubMed=19959593; DOI=10.1124/mol.109.060558;
RA   Clayton C.C., Bruchas M.R., Lee M.L., Chavkin C.;
RT   "Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the
RT   DRY motif reduces agonist efficacy.";
RL   Mol. Pharmacol. 77:339-347(2010).
RN   [43]
RP   FUNCTION, AND MUTAGENESIS OF SER-375.
RX   PubMed=21292762; DOI=10.1074/jbc.m110.177089;
RA   Zheng H., Chu J., Zhang Y., Loh H.H., Law P.Y.;
RT   "Modulating micro-opioid receptor phosphorylation switches agonist-
RT   dependent signaling as reflected in PKCepsilon activation and dendritic
RT   spine stability.";
RL   J. Biol. Chem. 286:12724-12733(2011).
CC   -!- FUNCTION: Receptor for endogenous opioids such as beta-endorphin and
CC       endomorphin (PubMed:11060299, PubMed:15944153, PubMed:16682964,
CC       PubMed:17384143, PubMed:17947509, PubMed:1846076, PubMed:18558479,
CC       PubMed:21292762, PubMed:7595566, PubMed:7678862, PubMed:8051154,
CC       PubMed:8240812, PubMed:8393525, PubMed:9224819, PubMed:9572309).
CC       Receptor for natural and synthetic opioids including morphine, heroin,
CC       DAMGO, fentanyl, etorphine, buprenorphin and methadone
CC       (PubMed:11060299, PubMed:15944153, PubMed:16682964, PubMed:17384143,
CC       PubMed:17947509, PubMed:1846076, PubMed:18558479, PubMed:21292762,
CC       PubMed:7595566, PubMed:7678862, PubMed:8051154, PubMed:8240812,
CC       PubMed:8393525, PubMed:9224819, PubMed:9572309). Also activated by
CC       enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe,
CC       with higher affinity for Met-enkephalin-Arg-Phe (PubMed:8624732).
CC       Agonist binding to the receptor induces coupling to an inactive GDP-
CC       bound heterotrimeric G-protein complex and subsequent exchange of GDP
CC       for GTP in the G-protein alpha subunit leading to dissociation of the
CC       G-protein complex with the free GTP-bound G-protein alpha and the G-
CC       protein beta-gamma dimer activating downstream cellular effectors
CC       (PubMed:16682964, PubMed:9224819). The agonist- and cell type-specific
CC       activity is predominantly coupled to pertussis toxin-sensitive G(i) and
CC       G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1
CC       and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G
CC       alpha proteins GNAZ and GNA15 (PubMed:9224819, PubMed:9572309). They
CC       mediate an array of downstream cellular responses, including inhibition
CC       of adenylate cyclase activity and both N-type and L-type calcium
CC       channels, activation of inward rectifying potassium channels, mitogen-
CC       activated protein kinase (MAPK), phospholipase C (PLC),
CC       phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K)
CC       and regulation of NF-kappa-B (PubMed:15944153, PubMed:21292762,
CC       PubMed:7595566, PubMed:9572309). Also couples to adenylate cyclase
CC       stimulatory G alpha proteins (PubMed:7595566). The selective temporal
CC       coupling to G-proteins and subsequent signaling can be regulated by
CC       RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members
CC       of the GPRK subfamily of Ser/Thr protein kinases and association with
CC       beta-arrestins is involved in short-term receptor desensitization
CC       (PubMed:11060299, PubMed:17384143, PubMed:17947509, PubMed:18558479).
CC       Beta-arrestins associate with the GPRK-phosphorylated receptor and
CC       uncouple it from the G-protein thus terminating signal transduction.
CC       The phosphorylated receptor is internalized through endocytosis via
CC       clathrin-coated pits which involves beta-arrestins. The activation of
CC       the ERK pathway occurs either in a G-protein-dependent or a beta-
CC       arrestin-dependent manner and is regulated by agonist-specific receptor
CC       phosphorylation (PubMed:11278523, PubMed:11896051, PubMed:15944153).
CC       Acts as a class A G-protein coupled receptor (GPCR) which dissociates
CC       from beta-arrestin at or near the plasma membrane and undergoes rapid
CC       recycling. Receptor down-regulation pathways are varying with the
CC       agonist and occur dependent or independent of G-protein coupling
CC       (PubMed:11060299, PubMed:17384143, PubMed:17947509, PubMed:18558479).
CC       Endogenous ligands induce rapid desensitization, endocytosis and
CC       recycling. Heterooligomerization with other GPCRs can modulate agonist
CC       binding, signaling and trafficking properties (PubMed:16682964,
CC       PubMed:17384143). {ECO:0000269|PubMed:11060299,
CC       ECO:0000269|PubMed:11278523, ECO:0000269|PubMed:11896051,
CC       ECO:0000269|PubMed:15944153, ECO:0000269|PubMed:16682964,
CC       ECO:0000269|PubMed:17384143, ECO:0000269|PubMed:17947509,
CC       ECO:0000269|PubMed:1846076, ECO:0000269|PubMed:18558479,
CC       ECO:0000269|PubMed:21292762, ECO:0000269|PubMed:7595566,
CC       ECO:0000269|PubMed:7678862, ECO:0000269|PubMed:8051154,
CC       ECO:0000269|PubMed:8240812, ECO:0000269|PubMed:8393525,
CC       ECO:0000269|PubMed:8624732, ECO:0000269|PubMed:9224819,
CC       ECO:0000269|PubMed:9572309}.
CC   -!- SUBUNIT: Forms homooligomers and heterooligomers with other GPCRs, such
CC       as OPRD1, OPRK1, OPRL1, NPFFR2, ADRA2A, SSTR2, CNR1 and CCR5 (probably
CC       in dimeric forms) (PubMed:10842167, PubMed:11896051, PubMed:14645661,
CC       PubMed:14729105, PubMed:16682964, PubMed:17384143). Interacts with
CC       heterotrimeric G proteins; interaction with a heterotrimeric complex
CC       containing GNAI1, GNB1 and GNG2 stabilizes the active conformation of
CC       the receptor and increases its affinity for endomorphin-2, the
CC       synthetic opioid peptide DAMGO and for morphinan agonists (By
CC       similarity). Interacts with PPL; the interaction disrupts agonist-
CC       mediated G-protein activation. Interacts (via C-terminus) with DNAJB4
CC       (via C-terminus). Interacts with calmodulin; the interaction inhibits
CC       the constitutive activity of OPRM1; it abolishes basal and attenuates
CC       agonist-stimulated G-protein coupling (By similarity). Interacts with
CC       FLNA, PLD2, RANBP9 and WLS and GPM6A (PubMed:12519790,
CC       PubMed:17548356). Interacts with RTP4 (By similarity). Interacts with
CC       SYP and GNAS (PubMed:15857684, PubMed:17005904). Interacts with RGS9,
CC       RGS17, RGS20, RGS4, PPP1R9B and HINT1 (By similarity).
CC       {ECO:0000250|UniProtKB:P35372, ECO:0000250|UniProtKB:P42866,
CC       ECO:0000269|PubMed:10842167, ECO:0000269|PubMed:11896051,
CC       ECO:0000269|PubMed:12519790, ECO:0000269|PubMed:14645661,
CC       ECO:0000269|PubMed:14729105, ECO:0000269|PubMed:15857684,
CC       ECO:0000269|PubMed:16682964, ECO:0000269|PubMed:17005904,
CC       ECO:0000269|PubMed:17384143, ECO:0000269|PubMed:17548356,
CC       ECO:0000269|PubMed:19324084}.
CC   -!- INTERACTION:
CC       P33535; Q812E9: Gpm6a; NbExp=7; IntAct=EBI-4392569, EBI-6113756;
CC       P33535; P70498: Pld2; NbExp=3; IntAct=EBI-4392569, EBI-6140589;
CC       P33535; P07825: Syp; NbExp=8; IntAct=EBI-4392569, EBI-976085;
CC       P33535; Q6P689: Wls; NbExp=2; IntAct=EBI-4392569, EBI-6113235;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:8240812,
CC       ECO:0000269|PubMed:8393525}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P42866}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:P97266}. Perikaryon
CC       {ECO:0000250|UniProtKB:P97266}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:P97266}. Endosome
CC       {ECO:0000250|UniProtKB:P97266}. Note=Is rapidly internalized after
CC       agonist binding. {ECO:0000250|UniProtKB:P97266}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=1;
CC         IsoId=P33535-1; Sequence=Displayed;
CC       Name=2; Synonyms=MOR1A;
CC         IsoId=P33535-2; Sequence=VSP_041828;
CC       Name=3; Synonyms=MOR1R;
CC         IsoId=P33535-3; Sequence=VSP_041829;
CC       Name=4; Synonyms=MOR1B;
CC         IsoId=P33535-4; Sequence=VSP_041830;
CC       Name=5; Synonyms=MOR1B2;
CC         IsoId=P33535-5; Sequence=VSP_041831;
CC       Name=6; Synonyms=MOR1C1;
CC         IsoId=P33535-6; Sequence=VSP_041832;
CC       Name=7; Synonyms=MOR-1C2;
CC         IsoId=P33535-7; Sequence=VSP_041833;
CC       Name=8; Synonyms=rMOR-1D;
CC         IsoId=P33535-8; Sequence=VSP_041834;
CC   -!- TISSUE SPECIFICITY: Brain. Is expressed in the cerebral cortex, caudate
CC       putamen, nucleus accumbens, septal nuclei, thalamus, hippocampus, and
CC       habenula. Not detected in cerebellum.
CC   -!- PTM: Phosphorylated. Differentially phosphorylated in basal and
CC       agonist-induced conditions. Agonist-mediated phosphorylation modulates
CC       receptor internalization. Phosphorylated by GRK2 in a agonist-dependent
CC       manner. Phosphorylation at Tyr-166 requires receptor activation, is
CC       dependent on non-receptor protein tyrosine kinase Src and results in a
CC       decrease in agonist efficacy by reducing G-protein coupling efficiency.
CC       Phosphorylated on tyrosine residues; the phosphorylation is involved in
CC       agonist-induced G-protein-independent receptor down-regulation.
CC       Phosphorylation at Ser-375 is involved in G-protein-dependent but not
CC       beta-arrestin-dependent activation of the ERK pathway.
CC       {ECO:0000269|PubMed:10488100, ECO:0000269|PubMed:10744734,
CC       ECO:0000269|PubMed:10820022, ECO:0000269|PubMed:11278523,
CC       ECO:0000269|PubMed:19959593}.
CC   -!- PTM: Ubiquitinated. A basal ubiquitination seems not to be related to
CC       degradation. Ubiquitination is increased upon formation of OPRM1:OPRD1
CC       oligomers leading to proteasomal degradation; the ubiquitination is
CC       diminished by RTP4. {ECO:0000250|UniProtKB:P42866}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ77387.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D16349; BAA03852.1; -; mRNA.
DR   EMBL; L20684; AAA41643.1; -; mRNA.
DR   EMBL; L13069; AAA41630.1; -; mRNA.
DR   EMBL; U02083; AAA70049.1; -; mRNA.
DR   EMBL; L22455; AAA16075.1; -; mRNA.
DR   EMBL; U35424; AAA79180.1; -; mRNA.
DR   EMBL; AY309003; AAQ77387.1; ALT_FRAME; mRNA.
DR   EMBL; AY309004; AAQ77388.1; -; mRNA.
DR   EMBL; AY225402; AAP44725.1; -; mRNA.
DR   EMBL; AY225403; AAP44726.1; -; mRNA.
DR   EMBL; AY309000; AAQ77384.1; -; mRNA.
DR   EMBL; AY309002; AAQ77386.1; -; mRNA.
DR   EMBL; S77863; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S75669; AAB33530.2; -; mRNA.
DR   PIR; I56504; I56504.
DR   PIR; I56517; I56517.
DR   PIR; S69010; S69010.
DR   RefSeq; NP_001033686.1; NM_001038597.2. [P33535-2]
DR   RefSeq; NP_001033688.2; NM_001038599.2. [P33535-5]
DR   RefSeq; NP_001033689.1; NM_001038600.2. [P33535-6]
DR   RefSeq; NP_001033690.1; NM_001038601.2. [P33535-7]
DR   RefSeq; NP_001291664.1; NM_001304735.1. [P33535-1]
DR   RefSeq; NP_001291666.1; NM_001304737.1. [P33535-1]
DR   RefSeq; NP_001291667.1; NM_001304738.1. [P33535-1]
DR   RefSeq; NP_001291669.1; NM_001304740.1. [P33535-1]
DR   RefSeq; NP_037203.1; NM_013071.2. [P33535-1]
DR   AlphaFoldDB; P33535; -.
DR   SMR; P33535; -.
DR   BioGRID; 247631; 5.
DR   CORUM; P33535; -.
DR   IntAct; P33535; 6.
DR   STRING; 10116.ENSRNOP00000068988; -.
DR   BindingDB; P33535; -.
DR   ChEMBL; CHEMBL270; -.
DR   DrugCentral; P33535; -.
DR   GuidetoPHARMACOLOGY; 319; -.
DR   GlyCosmos; P33535; 5 sites, No reported glycans.
DR   GlyGen; P33535; 5 sites.
DR   iPTMnet; P33535; -.
DR   PhosphoSitePlus; P33535; -.
DR   SwissPalm; P33535; -.
DR   PaxDb; 10116-ENSRNOP00000051290; -.
DR   GeneID; 25601; -.
DR   KEGG; rno:25601; -.
DR   AGR; RGD:3234; -.
DR   CTD; 4988; -.
DR   RGD; 3234; Oprm1.
DR   VEuPathDB; HostDB:ENSRNOG00000018191; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   InParanoid; P33535; -.
DR   OrthoDB; 5393360at2759; -.
DR   TreeFam; TF315737; -.
DR   Reactome; R-RNO-111885; Opioid Signalling.
DR   Reactome; R-RNO-202040; G-protein activation.
DR   Reactome; R-RNO-375276; Peptide ligand-binding receptors.
DR   Reactome; R-RNO-418594; G alpha (i) signalling events.
DR   PRO; PR:P33535; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000018191; Expressed in brain and 3 other cell types or tissues.
DR   ExpressionAtlas; P33535; baseline and differential.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0032839; C:dendrite cytoplasm; IDA:RGD.
DR   GO; GO:0032590; C:dendrite membrane; IDA:RGD.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:RGD.
DR   GO; GO:0098982; C:GABA-ergic synapse; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; IDA:RGD.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:SynGO.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:SynGO.
DR   GO; GO:0042383; C:sarcolemma; IDA:RGD.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IDA:RGD.
DR   GO; GO:0097444; C:spine apparatus; IDA:SynGO.
DR   GO; GO:0030315; C:T-tubule; IDA:RGD.
DR   GO; GO:0004979; F:beta-endorphin receptor activity; ISO:RGD.
DR   GO; GO:0004985; F:G protein-coupled opioid receptor activity; ISO:RGD.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IDA:RGD.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; ISS:UniProtKB.
DR   GO; GO:0031681; F:G-protein beta-subunit binding; IPI:RGD.
DR   GO; GO:0038047; F:morphine receptor activity; IDA:RGD.
DR   GO; GO:0042923; F:neuropeptide binding; IBA:GO_Central.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IMP:UniProtKB.
DR   GO; GO:0002438; P:acute inflammatory response to antigenic stimulus; IEP:RGD.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; ISO:RGD.
DR   GO; GO:0007197; P:adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway; IDA:GO_Central.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IDA:RGD.
DR   GO; GO:0031635; P:adenylate cyclase-inhibiting opioid receptor signaling pathway; IDA:RGD.
DR   GO; GO:0048149; P:behavioral response to ethanol; ISO:RGD.
DR   GO; GO:0042755; P:eating behavior; IMP:RGD.
DR   GO; GO:0044849; P:estrous cycle; IEP:RGD.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IDA:RGD.
DR   GO; GO:0038003; P:G protein-coupled opioid receptor signaling pathway; ISO:RGD.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:RGD.
DR   GO; GO:0006955; P:immune response; TAS:RGD.
DR   GO; GO:0007626; P:locomotory behavior; ISO:RGD.
DR   GO; GO:0106072; P:negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:RGD.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; ISS:UniProtKB.
DR   GO; GO:0033685; P:negative regulation of luteinizing hormone secretion; IMP:RGD.
DR   GO; GO:0045019; P:negative regulation of nitric oxide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0061358; P:negative regulation of Wnt protein secretion; ISS:UniProtKB.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IBA:GO_Central.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0032100; P:positive regulation of appetite; IMP:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; IMP:RGD.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0080135; P:regulation of cellular response to stress; ISO:RGD.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; IMP:UniProtKB.
DR   GO; GO:0042220; P:response to cocaine; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IDA:RGD.
DR   GO; GO:0032094; P:response to food; IEP:RGD.
DR   GO; GO:0070848; P:response to growth factor; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0035176; P:social behavior; IMP:RGD.
DR   GO; GO:0042713; P:sperm ejaculation; IDA:RGD.
DR   GO; GO:0019226; P:transmission of nerve impulse; ISO:RGD.
DR   CDD; cd15090; 7tmA_Mu_opioid_R; 1.
DR   Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000105; Mu_opioid_rcpt.
DR   InterPro; IPR001418; Opioid_rcpt.
DR   PANTHER; PTHR24229:SF7; MU-TYPE OPIOID RECEPTOR; 1.
DR   PANTHER; PTHR24229; NEUROPEPTIDES RECEPTOR; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00537; MUOPIOIDR.
DR   PRINTS; PR00384; OPIOIDR.
DR   SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Cell projection; Disulfide bond;
KW   Endosome; G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..398
FT                   /note="Mu-type opioid receptor"
FT                   /id="PRO_0000069978"
FT   TOPO_DOM        1..66
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TRANSMEM        67..91
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TOPO_DOM        92..104
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TRANSMEM        105..129
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TOPO_DOM        130..140
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TRANSMEM        141..163
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TOPO_DOM        164..183
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TRANSMEM        184..205
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TOPO_DOM        206..228
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TRANSMEM        229..253
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TOPO_DOM        254..277
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TRANSMEM        278..304
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TOPO_DOM        305..312
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TRANSMEM        313..336
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   TOPO_DOM        337..398
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   REGION          361..385
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           332..336
FT                   /note="NPxxY; plays a role in stabilizing the activated
FT                   conformation of the receptor"
FT                   /evidence="ECO:0000250|UniProtKB:P42866"
FT   MOD_RES         166
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19959593"
FT   MOD_RES         363
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11278523"
FT   MOD_RES         370
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:11278523"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11278523"
FT   MOD_RES         394
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000305|PubMed:10820022"
FT   LIPID           351
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        9
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        31
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        38
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        46
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        53
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        140..217
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         387..398
FT                   /note="LENLEAETAPLP -> VCAF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15525342"
FT                   /id="VSP_041828"
FT   VAR_SEQ         387..398
FT                   /note="LENLEAETAPLP -> GAEL (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_041829"
FT   VAR_SEQ         387..398
FT                   /note="LENLEAETAPLP -> KIVLF (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:7532594"
FT                   /id="VSP_041830"
FT   VAR_SEQ         387..398
FT                   /note="LENLEAETAPLP -> EPQSVET (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_041831"
FT   VAR_SEQ         387..398
FT                   /note="LENLEAETAPLP -> PALAVSVAQIFTGYPSPTHGEKPCKSYRDRPRPCGR
FT                   TWSLKSRAESNVEHFHCGAALIYNNVNFI (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15525342"
FT                   /id="VSP_041832"
FT   VAR_SEQ         387..398
FT                   /note="LENLEAETAPLP -> PALAVSVAQIFTGYPSPTHGEKPCKSYRDRPRPCGR
FT                   TWSLKSRAESNVEHFHCGAALIYNNELKIGPVSWLQMPAHVLVRPW (in isoform
FT                   7)"
FT                   /evidence="ECO:0000303|PubMed:15525342"
FT                   /id="VSP_041833"
FT   VAR_SEQ         387..398
FT                   /note="LENLEAETAPLP -> T (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:15525342"
FT                   /id="VSP_041834"
FT   MUTAGEN         91
FT                   /note="Y->A: Abolishes agonist-induced G-protein-
FT                   independent receptor internalization; when associated with
FT                   A-96, A-166 and A-336."
FT                   /evidence="ECO:0000269|PubMed:10488100"
FT   MUTAGEN         96
FT                   /note="Y->A: Abolishes agonist-induced G-protein-
FT                   independent receptor internalization; when associated with
FT                   A-91, A-166 and A-336."
FT                   /evidence="ECO:0000269|PubMed:10488100"
FT   MUTAGEN         114
FT                   /note="D->A,N: Impairs agonist affinity, agonist-induced
FT                   inhibition of adenylate cyclase and coupling to G-
FT                   proteins."
FT                   /evidence="ECO:0000269|PubMed:8051154,
FT                   ECO:0000269|PubMed:9224819"
FT   MUTAGEN         114
FT                   /note="D->E: No effect on inhibition of adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:8051154,
FT                   ECO:0000269|PubMed:9224819"
FT   MUTAGEN         147
FT                   /note="D->A: No effect on constitutive activation. Impairs
FT                   agonist affinity and agonist-induced inhibition of
FT                   adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:11580279,
FT                   ECO:0000269|PubMed:8051154"
FT   MUTAGEN         147
FT                   /note="D->E: Impairs agonist affinity and increases
FT                   agonist-induced inhibition of adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:11580279,
FT                   ECO:0000269|PubMed:8051154"
FT   MUTAGEN         147
FT                   /note="D->N: No effect on constitutive activation."
FT                   /evidence="ECO:0000269|PubMed:11580279,
FT                   ECO:0000269|PubMed:8051154"
FT   MUTAGEN         164
FT                   /note="D->E: Reduces basal activity."
FT                   /evidence="ECO:0000269|PubMed:11580279"
FT   MUTAGEN         164
FT                   /note="D->H,M,Q,Y: Constitutive active."
FT                   /evidence="ECO:0000269|PubMed:11580279"
FT   MUTAGEN         166
FT                   /note="Y->A: Abolishes agonist-induced G-protein-
FT                   independent receptor internalization; when associated with
FT                   A-91, A-96 and A-336."
FT                   /evidence="ECO:0000269|PubMed:10488100,
FT                   ECO:0000269|PubMed:19959593"
FT   MUTAGEN         166
FT                   /note="Y->F: Decrease in phosphorylation, no decrease in G-
FT                   protein binding."
FT                   /evidence="ECO:0000269|PubMed:10488100,
FT                   ECO:0000269|PubMed:19959593"
FT   MUTAGEN         180
FT                   /note="T->A: Impairs ARRB2- and GRK3-mediated receptor
FT                   desensitization."
FT                   /evidence="ECO:0000269|PubMed:11060299"
FT   MUTAGEN         275
FT                   /note="L->E: No effect on constitutive activation. Some
FT                   constitutive activity; when associated with K-279."
FT                   /evidence="ECO:0000269|PubMed:12356297"
FT   MUTAGEN         279
FT                   /note="T->D: Receptor inactivation."
FT                   /evidence="ECO:0000269|PubMed:11695897,
FT                   ECO:0000269|PubMed:12356297"
FT   MUTAGEN         279
FT                   /note="T->K: Constitutive active. Some constitutive
FT                   activity; when associated with E-275."
FT                   /evidence="ECO:0000269|PubMed:11695897,
FT                   ECO:0000269|PubMed:12356297"
FT   MUTAGEN         297
FT                   /note="H->A: Impairs agonist affinity and increases
FT                   agonist-induced inhibition of adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:8051154"
FT   MUTAGEN         336
FT                   /note="Y->A: Abolishes agonist-induced G-protein-
FT                   independent receptor internalization; when associated with
FT                   A-91, A-96 and A-166."
FT                   /evidence="ECO:0000269|PubMed:10488100"
FT   MUTAGEN         346
FT                   /note="C->A: No change in palmitoylation. No change in
FT                   palmitoylation; when associated with A-351."
FT                   /evidence="ECO:0000269|PubMed:9877183"
FT   MUTAGEN         351
FT                   /note="C->A: No change in palmitoylation; when associated
FT                   with A-346."
FT                   /evidence="ECO:0000269|PubMed:9877183"
FT   MUTAGEN         363
FT                   /note="S->A: Abolishes basal phosphorylation; when
FT                   associated with A-370. Abolishes basal and agonist-induced
FT                   phosphorylation; when associated with A-370 and A-375.
FT                   Accelerates agonist-induced receptor internalization."
FT                   /evidence="ECO:0000269|PubMed:11278523,
FT                   ECO:0000269|PubMed:18558479"
FT   MUTAGEN         370
FT                   /note="T->A: Abolishes basal phosphorylation; when
FT                   associated with A-363. Abolishes basal and agonist-induced
FT                   phosphorylation; when associated with A-363 and A-375.
FT                   Accelerates agonist-induced receptor internalization."
FT                   /evidence="ECO:0000269|PubMed:11278523,
FT                   ECO:0000269|PubMed:18558479"
FT   MUTAGEN         375
FT                   /note="S->A: Reduces agonist-induced receptor
FT                   internalization. Abolishes morphine-induced
FT                   phosphorylation. Restores agonist-specific PRKCE activity.
FT                   Abolishes basal and agonist-induced phosphorylation; when
FT                   associated with A-363 and A-370."
FT                   /evidence="ECO:0000269|PubMed:11278523,
FT                   ECO:0000269|PubMed:18558479, ECO:0000269|PubMed:21292762"
FT   MUTAGEN         394
FT                   /note="T->A: Impairs phosphorylation and abolishes agonist-
FT                   mediated acute receptor desensitization."
FT                   /evidence="ECO:0000269|PubMed:10488100,
FT                   ECO:0000269|PubMed:10820022"
FT   CONFLICT        237
FT                   /note="F -> G (in Ref. 6; AAA79180)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        238
FT                   /note="I -> V (in Ref. 7; AAQ77386)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        245
FT                   /note="V -> I (in Ref. 3; AAA41630, 4; AAA70049 and 10;
FT                   S77863)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   398 AA;  44494 MW;  9C916DE7C1C33743 CRC64;
     MDSSTGPGNT SDCSDPLAQA SCSPAPGSWL NLSHVDGNQS DPCGLNRTGL GGNDSLCPQT
     GSPSMVTAIT IMALYSIVCV VGLFGNFLVM YVIVRYTKMK TATNIYIFNL ALADALATST
     LPFQSVNYLM GTWPFGTILC KIVISIDYYN MFTSIFTLCT MSVDRYIAVC HPVKALDFRT
     PRNAKIVNVC NWILSSAIGL PVMFMATTKY RQGSIDCTLT FSHPTWYWEN LLKICVFIFA
     FIMPVLIITV CYGLMILRLK SVRMLSGSKE KDRNLRRITR MVLVVVAVFI VCWTPIHIYV
     IIKALITIPE TTFQTVSWHF CIALGYTNSC LNPVLYAFLD ENFKRCFREF CIPTSSTIEQ
     QNSTRVRQNT REHPSTANTV DRTNHQLENL EAETAPLP
//
